Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53, Brno, Czech Republic.
Med Oncol. 2012 Dec;29(5):3314-20. doi: 10.1007/s12032-012-0286-9. Epub 2012 Jun 30.
The incidence and mortality of renal cell carcinoma (RCC) in the Czech Republic are among the highest in the world. Several targeted agents have been recently approved for the treatment of advanced/metastatic RCC.
Presentation of a national clinical database for monitoring and assessment of patients with advanced/metastatic RCC treated with targeted therapy. The RenIS (RENal Information System, http://renis.registry.cz ) registry is a non-interventional post-registration database of epidemiological and clinical data of patients with RCC treated with targeted therapies in the Czech Republic. Twenty cancer centres eligible for targeted therapy administration participate in the project. As of November 2011, six agents were approved and reimbursed from public health insurance, including bevacizumab, everolimus, pazopanib, sorafenib, sunitinib, and temsirolimus. As of 10 October 2011, 1,541 patients with valid records were entered into the database. Comparison with population-based data from the Czech National Cancer Registry revealed that RCC patients treated with targeted therapy are significantly younger (median age at diagnosis 59 vs. 66 years). Most RenIS registry patients were treated with sorafenib and sunitinib, many patients sequentially with both agents. Over 10 % of patients were also treated with everolimus in the second or third line. Progression-free survival times achieved were comparable to phase III clinical trials. The RenIS registry has become an important tool and source of information for the management of cancer care and clinical practice, providing comprehensive data on monitoring and assessment of RCC targeted therapy on a national level.
捷克共和国的肾细胞癌（RCC）发病率和死亡率位居世界前列。最近，已有几种靶向药物被批准用于治疗晚期/转移性 RCC。
展示一个用于监测和评估接受靶向治疗的晚期/转移性 RCC 患者的国家临床数据库。RenIS（RENal Information System，http://renis.registry.cz）注册中心是一个非干预性的注册后数据库，用于收集捷克共和国接受靶向治疗的 RCC 患者的流行病学和临床数据。有 20 个癌症中心有资格进行靶向治疗，参与了该项目。截至 2011 年 11 月，有 6 种药物已被批准并通过公共医疗保险报销，包括贝伐单抗、依维莫司、帕唑帕尼、索拉非尼、舒尼替尼和替西罗莫司。截至 2011 年 10 月 10 日，已有 1541 名符合条件的患者被录入数据库。与捷克国家癌症登记处的基于人群的数据相比，接受靶向治疗的 RCC 患者明显更年轻（诊断时的中位年龄为 59 岁，而 66 岁）。大多数 RenIS 登记中心的患者接受索拉非尼和舒尼替尼治疗，许多患者还先后使用这两种药物。超过 10%的患者在二线或三线治疗中也接受依维莫司治疗。无进展生存期与 III 期临床试验相当。RenIS 登记中心已成为癌症管理和临床实践的重要工具和信息来源，为国家一级的 RCC 靶向治疗监测和评估提供了全面的数据。
